Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive LymphomaFrederick L. Locke, William Y. Go|Molecular Therapy|2017Cited by 616